Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials.

@article{Bitzer2009AddedBA,
  title={Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials.},
  author={Johannes Bitzer and Anna Maria Paoletti},
  journal={Clinical drug investigation},
  year={2009},
  volume={29 2},
  pages={
          73-8
        }
}
The ethinylestradiol 20 microg/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle], has been proven to be an effective and well tolerated contraceptive with an acceptable bleeding pattern and good safety profile. In addition, the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC prevents water-retention-related weight gain, and improves physical and emotional well-being… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

Similar Papers

Loading similar papers…